| 翻訳と辞書 |
Taksta
Taksta (previously CEM-102) is a front-loaded oral dosing regimen of sodium fusidate under development in the U.S. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).
==Clinical trials==
Jan 2010: Taksta has completed enrollment in a Phase 2 trial (due to run until March 2010) and is preparing for Phase 3 studies in the U.S. for acute bacterial skin structure infections (being compared with Linezolid).
Sep 2010: Taksta demonstrated comparable clinical success rates compared to linezolid in a Phase 2 trial in the U.S. for acute bacterial skin and skin structure infections.〔Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Still JG, Das A, Fernandes P (2011). "A randomized, double-blind Phase 2 study comparing the efficacy and safeety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections." Clinical Infectious Diseases 52(Supplement 7):S520-S226.〕
Jun 2011: Taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis.〔Wolfe CR. (2011) "Case report: treatment of chronic osteomyelitis." Clinical Infectious Diseases 52(Supplement 7):S538-S541.〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Taksta」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|